Payment overview · 2025
General Payments
$6,722.78
62 reported records · 24 companies
Healthcare provider profile · identity verified
Caleb Ray Birchler, D.O.
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · FAIRFIELD, OH · NPI 1366892994
Verified facts
What the public records show
CMS Open Payments records show Caleb Ray Birchler, D.O. received $6,722.78 in general payments during 2025 across 62 reported records.
AngioDynamics, Inc. accounted for 45.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $3,065.07 | 45.6% | 13 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$627.73 | 9.3% | 5 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $397.39 | 5.9% | 6 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $328.31 | 4.9% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $298.31 | 4.4% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $244.83 | 3.6% | 3 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $226.15 | 3.4% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $198.99 | 3.0% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $189.60 | 2.8% | 2 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $183.38 | 2.7% | 2 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $148.71 | 2.2% | 1 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $142.40 | 2.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $135.59 | 2.0% | 2 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $120.00 | 1.8% | 1 | 2025 |
| Haemonetics Corporation | Unresolved — no canonical attribution shown | $108.23 | 1.6% | 2 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $88.44 | 1.3% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $69.35 | 1.0% | 2 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $39.72 | 0.6% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $30.04 | 0.5% | 1 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $27.48 | 0.4% | 1 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $17.66 | 0.3% | 1 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $15.83 | 0.2% | 1 | 2025 |
| PolyNovo North America LLC | Unresolved — no canonical attribution shown | $14.90 | 0.2% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $4.67 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,990.16 | 55 |
| Travel and Lodging | $1,732.62 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ANGIOVAC Normalized: angiovac |
Device | AngioDynamics, Inc. | $1,780.60 | 2 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $1,110.57 | 8 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $627.73 | 5 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $397.39 | 6 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $216.34 | 3 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $216.34 | 3 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $198.99 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $189.60 | 2 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $183.38 | 2 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $173.90 | 3 | 2025 |
Source payment records
|
|||||
| ALIF Normalized: alif |
Device | Globus Medical, Inc. | $173.76 | 1 | 2025 |
Source payment records
|
|||||
| XLIF Normalized: xlif |
Device | Globus Medical, Inc. | $173.76 | 1 | 2025 |
Source payment records
|
|||||
| EXCELSIUS GPS Normalized: excelsius gps |
Device | Globus Medical, Inc. | $154.55 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $148.71 | 1 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER AAA Endoprosthesis Normalized: gore excluder aaa endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $142.40 | 1 | 2025 |
Source payment records
|
|||||
| XACT Normalized: xact |
Device | Abbott Laboratories | $138.18 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Stent Normalized: enroute transcarotid stent |
Device | Boston Scientific Corporation | $121.11 | 1 | 2025 |
Source payment records
|
|||||
| TEG6S HEMOSTASIS SYSTEM Normalized: teg6s hemostasis system |
Device | Haemonetics Corporation | $90.42 | 1 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $88.44 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $88.44 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $69.35 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $69.35 | 2 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $66.89 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $50.16 | 3 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $39.76 | 1 | 2025 |
Source payment records
|
|||||
| PREVENA Normalized: prevena |
Device | Solventum Corporation | $39.72 | 2 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $30.04 | 1 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $27.48 | 1 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C. VERAFLO Normalized: v a c veraflo |
Device | Solventum Corporation | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C.ULTA Normalized: v a c ulta |
Device | Solventum Corporation | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C. VERAFLO CLEANSE CHOICE Normalized: v a c veraflo cleanse choice |
Device | Solventum Corporation | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| NOVOSORB BTM Normalized: novosorb btm |
Device | PolyNovo North America LLC | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $14.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 38 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 30 |
| Atorvastatin Calcium | Atorvastatin Calcium | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | 13 |
| Xarelto | Rivaroxaban | 13 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,722.78 · 62 records | AngioDynamics, Inc. | ACTIV.A.C., ALIF, ALPHAVAC, ANGIOVAC, ARTEGRAFT VASCULAR GRAFT, ARTIX MT, AURYON LASER SYSTEM 100-120 VAC, Barostim Neo System, CLOTTRIEVER BOLD CATHETER, CT THROMBECTOMY SYSTEM KIT, ENDOCROSS Device, ENDURANT IIS, ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent, ESPRIT, EXCELSIUS GPS, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, GORE EXCLUDER AAA Endoprosthesis, Kerecis GraftGuide, Kerecis SurgiClose, NOVOSORB BTM, PREVENA, PURAPLY WOUND MATRIX, Penumbra System, Restrata Wound Matrix, RotarexS 6 F x 135 cm, SAPIEN 3 Ultra RESILIA, SYMPHONY CATHETER, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TEG6S HEMOSTASIS SYSTEM, Torus Stent Graft System, V.A.C. VERAFLO, V.A.C. VERAFLO CLEANSE CHOICE, V.A.C.ULTA, XACT, XIENCE SKYPOINT, XLIF | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error